Vanguard Capital Management
ADMA icon

Vanguard Capital Management’s ADMA Biologics ADMA Stock Holding History

Vanguard Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.6M Sell
10,103,809
-203,062
-2% -$1.85M ﹤0.01% 1645
2026
Q1 		$92.9M Buy
+10,306,871
New +$163M ﹤0.01% 1510

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management's ADMA Position: Q2 2026 in Review

Vanguard Capital Management reduced its ADMA Biologics (ADMA) stake by 2% in Q2 2026, selling an estimated $1.85M and leaving 10,103,809 shares worth $84.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1645.

Vanguard Capital Management first reported a position in ADMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $92.9M in Q1 2026. 320 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Vanguard Capital Management held 10,103,809 shares of ADMA Biologics worth $84.6M as of Q2 2026.
  • Vanguard Capital Management sold 203,062 ADMA Biologics shares in Q2 2026, an estimated $1.85M.
  • ADMA Biologics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1645 holding.
  • Vanguard Capital Management first reported a position in ADMA Biologics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's ADMA Biologics position peaked at $92.9M in Q1 2026.
  • 320 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.